Does oxytocin nasal spray work?
FAQA 2026 meta-analysis of 42 randomized trials, covering 1,922 people, found a small, non-significant effect of intranasal oxytocin on symptoms of mental disorders (g = 0.17, 95% CI −0.05 to 0.38). Whether sprayed oxytocin reaches the brain is still disputed, and the US nasal product, Syntocinon, is listed as discontinued.
On this page
What the trials found
The 2026 meta-analysis pooled double-blind randomized trials of intranasal oxytocin against placebo in autism, schizophrenia, substance use and other disorders. The overall effect was small and not statistically significant, with high variation between trials (I² = 77.4%). Removing two outlying substance-use studies shrank the estimate to g = 0.05 and removed that variation.
The best-known single study is older and narrower: a 2005 Nature paper reported that intranasal oxytocin increased trust in an economic game. It is one experiment, and the later clinical record has not turned that kind of finding into a consistent treatment effect.
Does a nasal dose reach the brain?
A 2013 study measured oxytocin in both blood and spinal fluid after a 24 IU nasal dose in 11 people, against 4 on placebo. Plasma levels peaked at 15 minutes; spinal-fluid levels took up to 75 minutes to rise significantly, and the two did not correlate (r < 0.10). A 2016 review argued that very little of the large amounts sprayed reaches the spinal fluid, while blood levels rise far above normal. A 2021 review set out the case that the route still has functional effects. The question remains open.
For what is reported about oxytocin's adverse effects, see oxytocin side effects.
Where the nasal product stands with regulators
Drugs@FDA lists Syntocinon nasal solution under NDA 012285 with the status discontinued, and DailyMed carries no nasal oxytocin label, so no US nasal product is marketed and no nasal label states a dose or bioavailability. Switzerland is different: a Swissmedic supply notice dated April 24, 2026, lists Syntocinon nasal spray at 40 IU/mL under a current authorization, number 25644.
What is sold
On October 7, 2026, Prof. Peptide counted oxytocin spray products at 3 of the 71 vendor catalogs it could read. These are research-market products, not the Swiss medicine, and nothing in the trials above describes them.
Sources
Primary
- Bonnieux J et al. Does intranasal oxytocin reduce symptoms of mental disorders? Neurosci Biobehav Rev 2026 (PMID 42134427) → — 42 trials, N = 1,922, g = 0.17; g = 0.05 without outliers
- Kosfeld M et al. Oxytocin increases trust in humans. Nature 2005 (PMID 15931222) → — the trust experiment (abstract read)
- Striepens N et al. Elevated cerebrospinal fluid and blood oxytocin following intranasal administration. Sci Rep 2013 (PMID 24310737) → — 24 IU, 11 vs 4, plasma 15 min, CSF up to 75 min, r < 0.10
- Drugs@FDA (openFDA), NDA 012285 Syntocinon nasal solution → — marketing status discontinued
Secondary
- Leng G, Ludwig M. Intranasal oxytocin: myths and delusions. Biol Psychiatry 2016 (PMID 26049207) → — the case that little reaches the spinal fluid
- Quintana DS et al. Advances in intranasal oxytocin research. Mol Psychiatry 2021 (PMID 32807845) → — the case for functional effects
- Swissmedic out-of-stock notice, April 24, 2026 (Syntocinon Nasenspray, authorization 25644) → — the current Swiss authorization and strength
For other common questions regarding oxytocin, see the full Oxytocin profile.
Where to Buy
Batch-traceable COAs · cold-chain shipping
cGMP/ISO labs · batch COAs
Public COAs · vendor-stated 99%+
Research use only. Not medical advice.
We may earn commissions from peptide vendor affiliate links.